http://rdf.ncbi.nlm.nih.gov/pubchem/reference/8898729

Outgoing Links

Predicate Object
contentType Clinical Trial|Clinical Trial, Phase I|Journal Article|Research Support, Non-U.S. Gov't
endingPage 59
issn 0007-0920
1532-1827
issueIdentifier 1
pageRange 54-59
publicationName British Journal of Cancer
startingPage 54
bibliographicCitation Penson RT, Seiden MV, Matulonis UA, Appleman LJ, Fuller AF, Goodman A, Campos SM, Clark JW, Roche M, Eder JP. A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours. British Journal of Cancer. 2005 Jun 28;93(1):54–9. doi: 10.1038/sj.bjc.6602671.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1df2ee85ae576194e97a61bfcd8dfb8f
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d2863c4d1afa7a65ec3de54de9bdf2b4
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_313639defedb360fc85e51da33bc43c2
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9197932c4126e6e6a80bd256b7e699cd
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8633287a4b5c88b0c23905e3e334fb41
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bb20ad6e56a4c0a8ada1e20a7e85e94e
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_410e1a4c800fa05016821a46ac24c92c
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ab58fdc8139f7f804f83ef997250532c
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e0b02aef4ef24640d941e54b2616f862
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_45a49ca41f07ec34d4d9a2dfdf6158bc
date 2005-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier https://doi.org/10.1038/sj.bjc.6602671
https://pubmed.ncbi.nlm.nih.gov/15986034
https://pubmed.ncbi.nlm.nih.gov/PMC2361482
isPartOf https://portal.issn.org/resource/ISSN/0007-0920
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/1765
https://portal.issn.org/resource/ISSN/1532-1827
language English
source https://pubmed.ncbi.nlm.nih.gov/
https://www.crossref.org/
https://scigraph.springernature.com/
title A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours
discusses http://id.nlm.nih.gov/mesh/M0029340
http://id.nlm.nih.gov/mesh/M0007930
hasSubjectTerm http://purl.org/au-research/vocabulary/anzsrc-for/2008/11
http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11445
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8167
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7706
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID36462
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9614
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9412
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60700
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8593

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129347572
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID135867281
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127719861
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129520161
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129586297
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129430288
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129125136
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128926582
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127741279

Total number of triples: 54.